Sporos and our group of portfolio companies are advancing a diversified pipeline of potential breakthrough therapies. Our focus is on cancer and serious immune disease, and through our vast network of scientific experts, we aim to identify first or best-in-class therapeutic approaches with the potential for significant patient impact.